Brief: Eris Lifesciences Sees Consol Revenue Growth Of 30% In FY23
Aug 5 (Reuters) - Eris Lifesciences Ltd ERIS.NS :
* SEES CONSOL REVENUE GROWTH OF 30% IN FY23
* SEES CONSOL EBIDTA GROWTH OF 16-17% IN FY23
Source text for Eikon: ID:nBSE4gV5V6
Further company coverage: ERIS.NS
((Reutersbriefs@thomsonreuters.com;))
Recent news on Eris Lifesciences
See all newsIndia's Eris Lifesciences gains on strong quarterly results
Brief: Eris Lifesciences Sept-Quarter Consol Net Profit 1.84 Billion Rupees
Brief: Eris Lifesciences Says Krishnakumar Vaidyanathan Resigns As Executive Director & COO
Brief: Eris Lifesciences Ltd Says June-Quarter Consol Net Profit 1.42 Billion Rupees
Brief: Eris Lifesciences March-Quarter Consol Net Profit 2.82 Billion Rupees